（来源：工人日报） 在中德合作领域，注重引进融合德国先进教育理念、教学模式和行业标准。平度市技师学院成立全省首 个"中德工匠学院"，率先实现中德智能制造人才的国际化培养。青岛市技师学院成立了机电一体化中德 实验班，构建"工学一体化"与"德国双元制"融合课程体系，推进德国认证标准本土化转化，提升专业国 际竞争力，培养支撑制造业转型升级的高素质人才。 依托青岛区位优势，锚定建设"国际门户枢纽城市"目标，青岛以技工教育国际合作为突破口，构建技能 人才国际培养平台，推动与全球20多个国家和地区的教育机构开展合作，高质量推进"技能出海"。 "使用钳子剥除电线外皮，利用万用表检测线路通断，再通过电脑编程控制电器开关、调节设备运行速 度……"青岛市技师学院实训车间内，来自老挝琅勃拉邦职业技术学院电气专业的教师莫达·奔永正在反 复练习，额头汗珠滑落却丝毫不敢分心。几天后，他通过了中国电工三级（高级工）职业技能等级考试 并获取证书。这张证书不仅是对他技能的认可，更寄托着他回国后推动本土教学标准提升的期望。 莫达·奔永的国际求学经历，是青岛技工教育"请进来"与"走出去"相结合的生动写照。 近年来，青岛以技工教育为纽带，持续深化多 ...

Group 1: Customer Collaboration - The company has been collaborating with customer G for several years, transitioning from consumer electronics to server business, with an order amount reaching hundreds of millions in 2025 [2] - For customer N, the company provides testing services for PCBA motherboards, with mass production expected to begin in 2025, and a projected equipment demand in the low four-digit range for 2026 [2][3] Group 2: Product Development and Progress - The company's liquid cooling module is currently used in testing equipment, with small batch shipments to customer N and plans to integrate it into cabinets [3] - The robotics business is addressing customer T's testing needs, with individual units priced over one million [3] Group 3: Revenue Expectations - In the AI server testing sector, the company anticipates significant growth, with a high revenue contribution from customers G and M in Q3 [3] - The automotive electronics business is expected to account for 20% of revenue in 2025, with continued market demand growth in 2026 [3][4] Group 4: Market Opportunities - In the consumer electronics sector, stable revenue is expected from testing equipment for mobile phones and tablets, with potential growth in AI glasses [4] - The company aims to transition to a component supplier, leveraging insights gained from collaboration with customer N to explore new market opportunities [4]

Group 1 - The core point of the news is that Bluestar Medical (002382) is proposing to lower the conversion price of its convertible bonds due to the stock price being below the required threshold for a certain period [1][2][4] - On January 8, 2026, Bluestar Medical's stock closed at 5.86 yuan, with a 1.21% increase, a turnover rate of 1.43%, a trading volume of 142,500 shares, and a transaction amount of 83.22 million yuan [1] - The company reported a net outflow of 285.43 million yuan from institutional investors and a net inflow of 432.3 million yuan from retail investors on January 8 [1][4] Group 2 - The Board of Directors of Bluestar Medical approved a proposal to lower the conversion price of the "Bluestar Convertible Bonds" due to the stock price being below 85% of the conversion price for at least 15 out of the last 30 trading days [1][2] - The proposed adjustment to the conversion price will be submitted for approval at the first extraordinary general meeting of shareholders in 2026, scheduled for January 26, 2026 [2] - The adjustment must be approved by more than two-thirds of the voting rights held by shareholders present at the meeting, and bondholders must abstain from voting [2]

Group 1 - The company held its 37th meeting of the sixth board of directors on January 7, 2026, via electronic communication, with all 8 directors participating [2][5] - The board proposed to lower the conversion price of the "Blue Sail Convertible Bond" due to the stock price being below 85% of the conversion price for at least 15 out of the last 30 trading days, triggering the condition for price adjustment [3][31][46] - The proposed adjustment will be submitted to the shareholders' meeting for approval, and the new conversion price must not be lower than the higher of the average stock price over the last 20 trading days before the meeting and the last trading day's price, as well as not lower than the latest audited net asset value per share and the par value [3][46] Group 2 - The company decided to hold its first extraordinary shareholders' meeting of 2026 on January 26, 2026, to discuss the proposed adjustment of the convertible bond conversion price [6][7] - The meeting will be conducted both in-person and via online voting, with specific time slots for voting provided [13][19] - Shareholders holding the convertible bonds must abstain from voting on the proposal to adjust the conversion price, which requires a two-thirds majority approval from the attending shareholders [15][46]

Group 1 - The company held its 37th meeting of the sixth board of directors on January 7, 2026, via electronic communication, with all 8 directors participating [2][3]. - The board proposed to lower the conversion price of the "Blue Sail Convertible Bond" due to the stock price being below 85% of the current conversion price for at least 15 out of the last 30 trading days [3][12][28]. - The proposed adjustment to the conversion price requires approval from the shareholders' meeting, and the new price must not be lower than the higher of the average stock price over the last 20 trading days before the meeting or the latest audited net asset value per share [3][28]. Group 2 - The company plans to hold its first extraordinary shareholders' meeting of 2026 on January 26, 2026, to discuss the proposed adjustment to the bond conversion price [6][7][32]. - The meeting will be conducted both in-person and via online voting, with specific time slots for voting outlined [34][45]. - Shareholders holding the convertible bonds must abstain from voting on the proposal to adjust the conversion price [40].

Group 1 - The core viewpoint of the articles revolves around recent corporate actions and updates regarding convertible bonds and shareholder activities [1][2][9]. Group 2 - Shareholder Sunshine Life intends to reduce its stake in Huakang Clean by no more than 3% [1]. - Baichuan Changyin's controlling shareholder plans to provide a financial support of up to RMB 48 million without interest or collateral to support the company's operational needs [1]. Group 3 - The last trading day for Liuyao convertible bonds is set for January 12, 2026 [2]. - Various convertible bonds are listed with their respective details, including their current prices, redemption prices, last trading days, and conversion values [3][5][7]. - Specific convertible bonds such as Huanxu Convertible Bond is subject to strong redemption, while Lanfan Convertible Bond proposes a down adjustment [9].

Group 1 - The company, Bluestar Medical, announced that its sixth board of directors held the thirty-seventh meeting, where it approved the proposal to lower the conversion price of "Bluestar Convertible Bonds" [2] - The board also approved the proposal to convene the first extraordinary shareholders' meeting of 2026 [2]

Investment Rating - The report indicates that the overall credit risk of the pharmaceutical manufacturing industry is controllable, with stable operating performance expected in 2026 [5][6][11]. Core Insights - The pharmaceutical manufacturing industry has shown a slight increase in the number of enterprises, with a deepening degree of differentiation within the industry. Revenue and total profit have remained stable year-on-year due to a stabilizing policy environment [6][11]. - The "14th Five-Year Plan" supports the development of innovative drugs, with the scale of license-out exceeding the total for 2024 in the first three quarters of 2025, indicating a positive outlook for innovative drug development [6][11]. - The industry has maintained net inflows in bond market financing, with overall debt pressure being manageable despite a significant amount of bonds maturing within one year [6][11]. Industry Fundamentals Industry Policy - The pharmaceutical industry is highly sensitive to policy changes, with a "three medical linkage" policy framework encouraging innovation, improving medical services, and optimizing medical insurance payments. The "14th Five-Year Plan" emphasizes the strategic importance of the biomanufacturing industry [7][8]. - Recent policies have focused on cost control in medical insurance, reforming payment methods, and promoting the development of generic drugs and innovative medicines [7][8]. Industry Operating Conditions - As of the end of 2024, the number of pharmaceutical manufacturing enterprises in China reached 9,793, with a slight increase in the number of loss-making enterprises, indicating a growing differentiation within the industry [12][11]. - The basic medical insurance fund's income and expenditure structure has improved, with significant cost control effects observed [11][12]. Financial Performance Growth Metrics - In 2024, the pharmaceutical manufacturing industry reported total revenue of 25,298.5 billion yuan and total profit of 3,420.7 billion yuan, with minor fluctuations expected in 2025 [22][23]. - For the first three quarters of 2025, total revenue was 18,211.4 billion yuan, a decrease of 2.00% year-on-year, while total profit was 2,534.8 billion yuan, down 0.70% [22][23]. Profitability - The gross profit margin for the pharmaceutical manufacturing industry has shown a declining trend, with the sales expense ratio remaining stable and the management expense ratio slightly decreasing [24][25]. - The net cash flow from operating activities has been declining, indicating potential liquidity risks [24][25]. Leverage and Solvency - The leverage level in the pharmaceutical manufacturing industry remains low, with a slight fluctuation observed in recent years. The debt-to-asset ratio has been stable, and the overall solvency indicators are at a high level [30][31]. - As of September 2025, the liquidity ratios have slightly improved, indicating a manageable debt repayment risk [31][32]. Bond Market Performance Issuance Overview - In 2025, the pharmaceutical manufacturing industry experienced a net inflow in bond market financing, with a total of 104 bonds issued amounting to 713.80 billion yuan [39][41]. - The industry has seen a concentration of bond issuers at the AA+ level, with a significant number of private enterprises involved [39][41].

证券日报网讯1月7日，蓝帆医疗（002382）发布公告称，公司将于2026年1月26日14：00召开2026年第 一次临时股东会。 ...

免责声明：本文内容与数据仅供参考，不构成投资建议，使用前请核实。据此操作，风险自担。 每日经济新闻 每经头条（nbdtoutiao）——十年首现，沪指连续站稳关键位置！高盛：建议高配中国股票！券商分析 师：人民币升值等因素加速跨境资本回流 （记者 曾健辉） 每经AI快讯，蓝帆医疗1月7日晚间发布公告称，公司第六届第三十七次董事会会议于2026年1月7日以 通讯表决的方式召开。会议审议了《关于召开2026年第一次临时股东会的议案》等文件。 ...